for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Walvax Biotechnology Co Ltd

300142.SZ

Latest Trade

45.81CNY

Change

-0.84(-1.80%)

Volume

48,581,778

Today's Range

44.53

 - 

47.07

52 Week Range

28.43

 - 

95.90

As of on the Shenzhen Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
46.65
Open
45.01
Volume
48,581,778
3M AVG Volume
1,311.47
Today's High
47.07
Today's Low
44.53
52 Week High
95.90
52 Week Low
28.43
Shares Out (MIL)
1,537.44
Market Cap (MIL)
72,002.03
Forward P/E
75.24
Dividend (Yield %)
0.04

Next Event

Q4 2020 Walvax Biotechnology Co Ltd Earnings Release

Latest Developments

More

Walvax Biotechnology Sees 2020 Net Profit Up 590-620% Y/Y

Walvax Technology To Cancel Review Of Proposal Related To Shanghai Zerun Biotechnology At Shareholders Meeting

Walvax Biotechnology Plans To Sell 32.6% Stake In Unit For 1.1 Bln Yuan

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Walvax Biotechnology Co Ltd

Walvax Biotechnology Co., Ltd. is a China-based company principally engaged in the research, development, production and distribution of vaccines, monoclonal antibodies and blood products. The Company’s main products include haemophilus influenza type b conjugate vaccines, freeze-dried group A,C meningococcal polysaccharide conjugate vaccines, group ACYW135 meningococcal polysaccharide vaccines and group A and C meningococcal polysaccharide vaccines, among others. The Company distributes its products mainly in domestic market.

Industry

Biotechnology & Drugs

Contact Info

19F, Tower A, Building 9

Dingyi Tiancheng, No.99, Keyuan Road

Hi-Tech Zone

KUNMING, YUN

650106

China

+86.871.68312779

http://www.walvax.com/

Executive Leadership

Yunchun Li

Chairman of the Board

Runsheng Jiang

President, Director

Zhen Huang

Vice Chairman of the Board

Hua Zhou

Chief Financial Officer

Yunyan Wu

Chief Operating Officer

Key Stats

1.63 mean rating - 8 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2017

0.7K

2018

0.9K

2019

1.1K

2020(E)

3.6K
EPS (CNY)

2017

-0.349

2018

0.680

2019

0.092

2020(E)

0.620
Price To Earnings (TTM)
158.09
Price To Sales (TTM)
38.09
Price To Book (MRQ)
12.42
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.69
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
10.25
Return on Equity (TTM)
7.37

Latest News

Latest News

BRIEF-Shenzhen Exchange Filing Shows Block Trade Of Walvax Biotechnology's Shares Involving 597.7 Mln Yuan

* BLOCK TRADE OF WALVAX BIOTECHNOLOGY CO LTD'S 12.6 MILLION SHARES INVOLVING 597.7 MILLION YUAN ($84.37 million) ON JUNE 17 Source text in Chinese: https://bit.ly/3fvQH63 Further company coverage: ($1 = 7.0846 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Shenzhen Stock Exchange Filing Shows Block Trade Of Walvax Biotechnology's Shares Involving 323.0 Mln Yuan

* BLOCK TRADE OF WALVAX BIOTECHNOLOGY CO LTD'S 8.0 MILLION SHARES INVOLVING 323.0 MILLION YUAN ($45.53 million) ON MAY 14 Source text in Chinese: https://bit.ly/3fWUNFw Further company coverage: ($1 = 7.0942 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Walvax Biotechnology, Suzhou Abogen Biosciences To Develop MRNA Vaccine For New Coronavirus

* SAYS IT AND SUZHOU ABOGEN BIOSCIENCES AGREE TO DEVELOP MRNA VACCINE FOR NEW CORONAVIRUS Source text in Chinese: https://bit.ly/2yOo2JQ Further company coverage: (Reporting by Hong Kong newsroom)

China approves home-grown vaccines, offering alternative to global drugmakers' products

(This Dec 31 story corrects to show GSK did not participate in the development of Cecolin, in sixth and seventh paragraph.)

CORRECTED-China approves sales of first domestically developed 13-valent pneumonia vaccine

China has approved a pneumonia vaccine developed by domestic drugmaker Walvax Biotechnology , its National Medical Products Administration said in a notice on Tuesday, offering an alternative to Pfizer's market-dominating Prevnar 13.

BRIEF-Walvax Biotechnology's Prelim 2017 Net Loss Of 535.02 Mln Yuan

* SAYS PRELIM 2017 NET LOSS OF 535.02 MILLION YUAN ($84.83 million) VERSUS NET PROFIT OF 70.46 MILLION YUAN YEAR AGO Source text in Chinese: http://bit.ly/2ETkN1v Further company coverage: ($1 = 6.3070 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up